Phathom Pharmaceuticals Inc
PHAT11.750USD
+0.750+6.82%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
823.73MMarket Cap
LossP/E TTM
More Details of Phathom Pharmaceuticals Inc Company
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
Ticker SymbolPHAT
Company namePhathom Pharmaceuticals Inc
IPO dateOct 25, 2019
CEOMr. Steven Basta
Number of employees427
Security typeOrdinary Share
Fiscal year-endOct 25
Address100 Campus Drive
CityFLORHAM PARK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code07932
Phone18777428466
Websitehttps://www.phathompharma.com/
Ticker SymbolPHAT
IPO dateOct 25, 2019
CEOMr. Steven Basta
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
36.01K
-22.58%
Mr. Mark Stenhouse
Mr. Mark Stenhouse
Independent Director
Independent Director
30.00K
+53.85%
Mr. Theodore R. (Ted) Schroeder
Mr. Theodore R. (Ted) Schroeder
Independent Director
Independent Director
21.00K
--
Ms. Anne Marie Cook, J.D.
Ms. Anne Marie Cook, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Ms. Heidi K. Kunz
Ms. Heidi K. Kunz
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Azmi Nabulsi
Dr. Azmi Nabulsi
Co-Founder, Chief Operating Officer
Co-Founder, Chief Operating Officer
929.34K
-2.52%
Dr. Asit Parikh, M.D., Ph.D.
Dr. Asit Parikh, M.D., Ph.D.
Independent Director
Independent Director
113.50K
+10.19%
Mr. Frank L. Karbe
Mr. Frank L. Karbe
Independent Director
Independent Director
67.50K
+18.42%
Ms. Molly Henderson, CPA
Ms. Molly Henderson, CPA
Chief Financial and Business Officer
Chief Financial and Business Officer
62.79K
-43.33%
Mr. Michael F. (Mike) Cola
Mr. Michael F. (Mike) Cola
Independent Chairman of the Board
Independent Chairman of the Board
39.80K
+35.84%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
36.01K
-22.58%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
17.18%
Medicxi Ventures (UK) LLP
10.52%
Millennium Management LLC
5.86%
Abingworth Management Limited
4.93%
Invesco Advisers, Inc.
4.57%
Other
56.93%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
17.18%
Medicxi Ventures (UK) LLP
10.52%
Millennium Management LLC
5.86%
Abingworth Management Limited
4.93%
Invesco Advisers, Inc.
4.57%
Other
56.93%
Shareholder Types
Shareholders
Proportion
Venture Capital
22.13%
Investment Advisor
18.82%
Private Equity
17.78%
Hedge Fund
12.24%
Investment Advisor/Hedge Fund
11.28%
Individual Investor
4.24%
Research Firm
1.31%
Bank and Trust
0.26%
Pension Fund
0.15%
Other
11.80%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
318
61.93M
88.60%
-20.64M
2025Q1
321
68.36M
98.42%
-14.76M
2024Q4
311
70.95M
103.79%
-11.79M
2024Q3
293
76.11M
113.29%
+9.50M
2024Q2
284
61.82M
105.14%
-1.53M
2024Q1
280
58.85M
100.56%
-3.74M
2023Q4
274
57.52M
100.58%
-4.32M
2023Q3
267
60.33M
119.18%
-6.87M
2023Q2
263
58.95M
120.15%
+1.98M
2023Q1
253
46.63M
112.72%
-8.47M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
11.97M
17.15%
+1.86M
+18.44%
May 09, 2025
Medicxi Ventures (UK) LLP
7.46M
10.69%
--
--
Mar 31, 2025
Abingworth Management Limited
3.50M
5.01%
--
--
Mar 31, 2025
Invesco Advisers, Inc.
3.35M
4.8%
-18.45K
-0.55%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.91M
4.17%
-168.44K
-5.47%
Mar 31, 2025
The Vanguard Group, Inc.
2.77M
3.97%
-874.00
-0.03%
Mar 31, 2025
Ensign Peak Advisors, Inc.
2.51M
3.6%
-12.77K
-0.51%
Mar 31, 2025
683 Capital Management LLC
1.45M
2.07%
+420.00K
+40.98%
Mar 31, 2025
New Enterprise Associates (NEA)
1.96M
2.81%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
